ArticleThe Journal of infectious diseases2025
Associations Between Ticagrelor Use and the Risk of Infections: A Mendelian Randomization Study.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary biliary cirrhosis and inflammatory bowel disease: a two-sample bidirectional Mendelian randomization study.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Blood metabolomic and postpartum depression: a mendelian randomization study.BMC pregnancy and childbirth · 2024Article
Corrections and comments
- Retraction · 2024-08-06Concerns/Issues about Results and/or Conclusions · Error in Analyses · Error in Results and/or Conclusions · Investigation by Journal/Publisher · Investigation by Third Party ·
- Commented on by
- Retracted
Authors and funding
5 authors.
Funding
Abstract
backgroundWe conducted a Mendelian randomization (MR) study to elucidate the anti-infective effects of ticagrelor.
methodsSingle-nucleotide polymorphisms (SNPs) associated with serum levels of ticagrelor or its major metabolite AR-C124910XX (ARC) in the Platelet Inhibition and Patient Outcomes trial were selected as genetic proxies for ticagrelor exposure. Positive control analyses indicated that genetically surrogated serum ticagrelor levels (6 SNPs) but not ARC levels (2 SNPs) were significantly associated with lower risks of coronary heart disease. Therefore, the 6 SNPs were used as genetic instruments for ticagrelor exposure, and the genome-wide association study data for 5 infection outcomes were derived from the UK Biobank and FinnGen consortium.
resultsThe 2-sample MR analyses based on inverse variance-weighted methods indicated that genetic liability to ticagrelor exposure could reduce the risk of bacterial pneumonia (odds ratio, 0.82; 95% CI, .71-.95; P = 8.75E-03) and sepsis (odds ratio, 0.83; 95% CI, .73-.94; P = 3.69E-03); however, no causal relationship was detected between ticagrelor exposure and upper respiratory infection, pneumonia, and urinary tract infection. Extensive sensitivity analyses corroborated these findings.
conclusionsOur MR study provides further evidence for the preventive effects of ticagrelor on bacterial pneumonia and sepsis.
Indexed as
Identifiers
38586880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.